Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $13.8 million.

  • Cartesian Therapeutics' Total Current Liabilities fell 3551.51% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year decrease of 3551.51%. This contributed to the annual value of $23.0 million for FY2024, which is 6631.53% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Total Current Liabilities stood at $13.8 million for Q3 2025, which was down 3551.51% from $12.3 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Total Current Liabilities registered a high of $95.6 million during Q3 2021, and its lowest value of $12.3 million during Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' median Total Current Liabilities value was $26.5 million (recorded in 2023), while the average stood at $39.7 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Total Current Liabilities surged by 28780.99% in 2021, and later crashed by 7518.41% in 2022.
  • Over the past 5 years, Cartesian Therapeutics' Total Current Liabilities (Quarter) stood at $72.3 million in 2021, then tumbled by 65.29% to $25.1 million in 2022, then skyrocketed by 172.0% to $68.2 million in 2023, then crashed by 66.32% to $23.0 million in 2024, then plummeted by 39.92% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $12.3 million for Q2 2025, and $15.0 million during Q1 2025.